Drug of the Day

When a brand-name drug loses its patent protection, the floodgates open. Ibuprofen—the common pain reliever found in Children's Motrin and Junior Strength Motrin—illustrates this perfectly: it now faces 188 generic competitors in the U.S. market. This wasn't always the case. When Kenvue Brands (the current sponsor) held exclusive rights to sell these formulations, they controlled the market. But once the patent expired, competitors filed Paragraph IV challenges—legal declarations that they could manufacture identical versions without infringing patents. Each approved competitor drives prices lower. Ibuprofen itself is a nonsteroidal anti-inflammatory drug (NSAID), meaning it reduces pain, fever, and inflammation by blocking certain body chemicals. It typically works within an hour, making it popular for everything from headaches to menstrual cramps. The 188 generic versions available today look and work identically to the original brand. Yet they cost a fraction of the price—a dramatic difference from when Kenvue had exclusive distribution rights. This story reveals something fundamental about how medicines actually become affordable: not through price negotiations alone, but through the deliberate expiration of patent monopolies that allow competition to flourish.

Heparin sodium has received 532 supplemental approvals—more than nearly any other drug on the market. For context, most medications get a handful. What explains this extraordinary number? Heparin, a blood thinner derived from animal tissue, first earned FDA approval in 1975. But that wasn't the end of its story. Over the following decades, doctors and researchers discovered new ways to use it: different dosages for different patients, new formulations without preservatives, applications in specialized medical settings, and safety refinements based on real-world experience. Each of these discoveries triggered a supplemental approval—a formal FDA process updating the drug's label and permitted uses. A patient on dialysis needs different heparin dosing than someone preventing blood clots after surgery. Cancer patients have different requirements than cardiac patients. A preservative-free version matters for certain vulnerable populations. This isn't bureaucratic bloat. These 532 approvals represent decades of active clinical development, safety monitoring, and precision medicine in action. Heparin's long approval history reveals something crucial: the most important drugs in medicine aren't one-hit wonders, but living, evolving treatments refined through continuous study and real-world use.